Skip to content
ABOUT
AUTHOR GUIDELINES
AUTHORS/EDITORS
SUBSCRIPTIONS
CONTACT US
MY ACCOUNT
Facebook
X
LinkedIn
Instagram
Search
×
HOME
PSYCH. BULLETIN
LATEST ISSUE
BLACK BOOK OF DOSING & MONITORING
RATING SCALES
LICENSING INFORMATION
RESOURCES
PSYCHOTROPICS A-Z
PSYCHOPHARMACOLOGY 101
NEWS
Diagnosis and Treatment of Depression in the Cancer Patient
1
x
$
0.00
Cariprazine to Treat Schizophrenia and Bipolar Disorder in Adults
1
x
$
30.00
Cannabis Pen-Induced Psychosis in a First-Time Adolescent User
1
x
$
30.00
Breast Imaging: Economic Issues and Challenges
1
x
$
0.00
Assessing the Older Cancer Patient
1
x
$
0.00
Carlos A. Zarate, MD: Modulators of the Glutamatergic System: Implications for the Development of Improved Therapeutics in Mood Disorders
1
x
$
30.00
Antidepressant Induced Apathy Responsive to Dose Reduction
1
x
$
30.00
A Pilot Evaluating Clinical Pharmacy Services in an Ambulatory Psychiatry Setting
1
x
$
30.00
Successful Management of Psychotropics Induced Stuttering Priapism with Pseudoephedrine in a Patient with Schizophrenia
1
x
$
30.00
Paroxetine Treatment of Major Depressive Disorder
1
x
$
30.00
Gregory J. Moore, PhD: Magnetic Resonance Spectroscopy: Neurochemistry and Treatment Effects in Affective Disorders
1
x
$
30.00
Effectiveness of Clozapine use in Delaying Hospitalization in Routine Clinical Practice: A 2 year Observational Study
1
x
$
30.00
Vicki L. Ellingrod, PharmD, BCPP: 5-HT2A Receptor Promoter Polymorphism, -1438G/A and Negative Symptom Response to Olanzapine in Schizophrenia
1
x
$
30.00
View Cart
Checkout
Home
Store
“Vicki L. Ellingrod, PharmD, BCPP: 5-HT2A Receptor Promoter Polymorphism, -1438G/A and Negative Symptom Response to Olanzapine in Schizophrenia” has been added to your cart.
View cart
Sort by
Name
Sort by
Name
Sort by
Price
Sort by
Date
Sort by
Popularity
Show
20 Products
Show
20 Products
Show
40 Products
Show
60 Products
Divalproex in the Treatment of Migraine
$
30.00
Add to cart
Details
Do Long-Acting Injectable Antipsychotics Prevent or Delay Hospital Readmission?
$
30.00
Add to cart
Details
Does Isotretinoin Cause Depression and Suicide? By J. Douglas Bremner, MD
$
0.00
Add to cart
Details
Donald S. Robinson, MD: Monoamine Oxidase Inhibitors: A New Generation
$
30.00
Add to cart
Details
Donald S. Robinson, MD: Treatment Effects of Selegiline Transdermal System on Symptoms of Major Depressive Disorder: A Meta-Analysis of Short-Term, Placebo-Controlled, Efficacy Trials
$
30.00
Add to cart
Details
Dose-Dependent Urinary Incontinence with Sertraline Use in Obsessive-Compulsive Disorder
$
30.00
Add to cart
Details
Douglas G. Kondo, MD: An Evidence-Based Medicine Approach to Combined Treatment for ADHD in Children and Adolescents
$
30.00
Add to cart
Details
Dr. Juan E. Mezzich y Dr. Miguel R. Jorge: ¡Bienvenidos a Psiquiatría y Salud Integral!
$
0.00
Add to cart
Details
Drug Development for Anxiety Disorders: New Roles for Atypical Antipsychotics
$
30.00
Add to cart
Details
Drug Induced Mania in a Boy with High Functioning Autism
$
30.00
Add to cart
Details
Drug–Drug Interactions Associated with Second-Generation Antipsychotics: Considerations for Clinicians and Patients
$
30.00
Add to cart
Details
Duloxetine for the Treatment of Major Depressive Disorder
$
30.00
Add to cart
Details
Duloxetine in Military Posttraumatic Stress Disorder
$
30.00
Add to cart
Details
Duration of Untreated Illness in Obsessive-Compulsive Disorder and its Associated Factors
$
30.00
Add to cart
Details
E. Chris Muly, MD, PhD: Signal Transduction Abnormalities in Schizophrenia: the cAMP System
$
30.00
Add to cart
Details
Early Positive Report of Viloxazine for a Child with Hyperkinetic Autism
$
30.00
Add to cart
Details
Early-Life Adversity, CRF Dysregulation, and Vulnerability to Mood and Anxiety Disorders
$
30.00
Add to cart
Details
Economic Impacts of Anxiety Disorders
$
0.00
Add to cart
Details
Economics of Cancer Drug Development
$
0.00
Add to cart
Details
EDITOR’S LETTER: Charles B. Nemeroff, MD, PhD
$
0.00
Add to cart
Details
Previous
1
…
11
12
13
…
44
Next
Page load link
Go to Top
